Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.67 |
| ▸ | KDM5A | P29375 | 9/20 | 0.65 |
| ▸ | KDM5B | Q9UGL1 | 9/20 | 0.65 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.57 |
| ▸ | KDM4A | O75164 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033410 | 0.88 | KDM2B (0.74) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16033033 | 0.88 | KDM4C (0.69) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16034727 | 0.88 | KDM4C (0.68) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16033795 | 0.85 | KDM2B (0.64) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16033424 | 0.81 | KDM2B (1.00) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16034328 | 0.79 | KDM5A (1.00) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16033404 | 0.79 | KDM2B (0.64) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16033654 | 0.77 | KDM2B (0.61) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16033213 | 0.77 | KDM5A (1.00) | KDM2BKDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16034190 | 0.75 | KDM5A (0.71) | KDM2BKDM5AKDM5BKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9701657-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE PHARMACEUTICALS INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527829-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-05-05 | — | — | US | disclosed |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 19/4885KDM5A 8/4885KDM5B 10/4885 |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 19/4885KDM5A 8/4885KDM5B 10/4885 |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 19/4885KDM5A 8/4885KDM5B 10/4885 |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 19/4885KDM5A 8/4885KDM5B 10/4885 |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 19/4885KDM5A 8/4885KDM5B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.